Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.

Abstract

Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels. Long-term colestipol therapy in conjunction with diet may reduce xanthoma size, arrest progression of coronary artery atherosclerosis, and may reduce mortality from coronary heart disease. Probucol, a bisphenol cholesterol-lowering drug, is an effective cholesterol-lowering agent that reduces levels of HDL cholesterol, HDL cholesterol, and apoprotein A-1, the major apolipoprotein of HDL. Because HDL cholesterol is independently and inversely associated with development of coronary heart disease, the ramifications of simultaneous lowering of LDL and HDL cholesterol levels by probucol treatment need further study. Long-term, placebo-controlled studies of repetitive coronary arteriography, coronary heart disease morbidity and mortality, or both are needed to ascertain the efficacy of long-term probucol use in relation to development of atherosclerosis.

• Authors: C J Glueck
• Journal: Annals of internal medicine (Ann Intern Med) Vol. 96 Issue 4 Pg. 475-82 (Apr 1982) ISSN: 0003-4819 [Print] United States
• PMID: 7039445 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Nicotinic Acids
• Phenols
• Polyamines
• Niacin
• Cholesterol
• Colestipol
• Probucol

Topics

• Arteriosclerosis (drug therapy)
• Cholesterol (metabolism)
• Colestipol (adverse effects, therapeutic use)
• Drug Therapy, Combination
• Humans
• Hypercholesterolemia (drug therapy)
• Hyperlipoproteinemia Type II (drug therapy)
• Niacin
• Nicotinic Acids (therapeutic use)
• Phenols (therapeutic use)
• Polyamines (therapeutic use)
• Probucol (adverse effects, therapeutic use)